Evidence map›Paper›PMID 37379350›Full record

ArticlePLoS neglected tropical diseases2023

Impact of a bi-annual community-directed treatment with ivermectin programme on the incidence of epilepsy in an onchocerciasis-endemic area of Mahenge, Tanzania: A population-based prospective study.

Dan Bhwana, Luís-Jorge Amaral, Athanas Mhina, Paul Martine Hayuma, Filbert Francis, Joseph N Siewe Fodjo, Bruno P Mmbando, Robert Colebunders

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Epilepsy in low- to middle-income countries.Current opinion in neurology · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Onchocerciasis-associated epilepsy and biomarkers.PLoS neglected tropical diseases · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. The onchocerciasis hypothesis of nodding syndrome.PLoS neglected tropical diseases · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Dan BhwanaNational Institute for Medical Research, Tanga, Tanzania.
Luís-Jorge AmaralGlobal Health Institute, University of Antwerp, Antwerp, Belgium.
Athanas MhinaNational Institute for Medical Research, Tanga, Tanzania.
Paul Martine HayumaNational Institute for Medical Research, Tanga, Tanzania.
Filbert FrancisNational Institute for Medical Research, Tanga, Tanzania.
Joseph N Siewe FodjoGlobal Health Institute, University of Antwerp, Antwerp, Belgium.
Bruno P MmbandoNational Institute for Medical Research, Tanga, Tanzania.
Robert ColebundersGlobal Health Institute, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-1919-1340
National Institute for Medical Research · TZUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommunity-directed treatment with ivermectin (CDTi) is used to eliminate onchocerciasis. However, despite 25 years of annual CDTi in Mahenge, Tanzania, the prevalence of onchocerciasis and onchocerciasis-associated epilepsy remained high in certain rural villages. Therefore, in 2019, bi-annual CDTi was introduced in the area. This study assessed the impact of the programme on the incidence of epilepsy in four villages. METHODOLOGY: Door-to-door epilepsy surveys were conducted prior to (2017/18) and after (2021) implementing a bi-annual CDTi program. All household members were screened for epilepsy symptoms using a validated questionnaire, and suspected cases were examined by a medical doctor to confirm/reject the diagnosis of epilepsy. The prevalence and annual incidence of epilepsy, including nodding syndrome, were calculated with 95% Wilson confidence intervals with continuity correction. The latter was also done for CDTi coverage in 2016 and 2021.

resultsPrecisely 5,444 and 6,598 persons were screened for epilepsy before and after implementing the intervention. The CDTi coverage of the overall population was 82.3% (95%CI: 81.3-83.2%) in 2021 and sustained in both distribution rounds (81.5% and 76.8%). The coverage was particularly high in children and teenagers aged 6 to 18 years (93.2%, 95%CI: 92.1-94.2%). The epilepsy prevalence remained similar: 3.3% (95%CI: 2.9-3.9%) in 2017/18 versus 3.1% (95%CI: 2.7-3.5%) in 2021. However, the incidence of epilepsy declined from 177.6 (95%CI: 121.2-258.5) in 2015-2017 and 2016-2018 to 45.5 (95%CI: 22.2-89.7) in 2019-2021 per 100,000 persons-years. The incidence of probable nodding syndrome varied from 18.4 (95%CI: 4.7-58.5) to 5.1 (95%CI: 0.3-32.8). None of the nine incidence cases of epilepsy for which information on ivermectin intake was available took ivermectin in the year they developed their first seizures.

conclusionA bi-annual CDTi programme should be implemented in areas with high prevalence of onchocerciasis and epilepsy. High CDTi coverage among children is particularly important to prevent onchocerciasis-associated epilepsy.

Indexed as

EpilepsyNodding SyndromeOnchocerciasisAdolescentAntiparasitic AgentsChildHumansIncidenceIvermectinPrevalenceProspective StudiesTanzaniaAntiparasitic AgentsIvermectin

Identifiers

PMID37379350
PMCPMC10335697
OpenAlexW4382361812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.